Cymabay Therapeu (CBAY) Stock
CBAY is no longer traded. Cymabay Therapeu was acquired by Gilead Sciences (GILD) on March 22, 2024.
Each CBAY share was exchanged for $32.50 in cash. Prices on this page are historical; the last trade was March 21, 2024 at $32.48.
See Gilead Sciences (GILD) stock →Cymabay Therapeu stock price history
CBAY final trading statistics
- Final close
- $32.48
- Final trading day
- Mar 21, 2024
- Market cap at delisting
- $3.73B
- Shares outstanding
- 114.78M
- Final 52-week range
- $7.26 – $32.50
- Avg. volume (final 3 mo.)
- 3,903,508
- All-time high (split-adj.)
- $32.48 · Mar 2024
- All-time low (split-adj.)
- $0.93 · Feb 2016
- Return since IPO
- +260.9%
- Beta
- 0.32
- Book value / share
- $2.57
- Price / book
- 12.65
Cymabay Therapeu annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2023 | $31.07M | -$105.4M | -$0.97 |
| FY2022 | $31.02M | -$118.9M | -$1.21 |
| FY2021 | $0.00 | -$92.6M | -$1.26 |
| FY2020 | $0.00 | -$48.7M | -$0.75 |
| FY2019 | $0.00 | -$102.2M | -$1.45 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Cymabay Therapeu
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California. As of March 22, 2024, CymaBay Therapeutics, Inc. operates as a subsidiary of Gilead Sciences, Inc.
Cymabay Therapeu stock FAQ
What happened to Cymabay Therapeu stock?
Cymabay Therapeu was acquired by Gilead Sciences (GILD) on March 22, 2024. Shareholders received $32.50 in cash for each share. CBAY stock stopped trading on the Nasdaq, with a final close of $32.48 on March 21, 2024.
What did Cymabay Therapeu shareholders receive?
Each CBAY share was converted into $32.50 in cash. The deal was valued at about $4.3 billion.
Is CBAY stock still trading?
No. CBAY was delisted from the Nasdaq on March 22, 2024 and no longer trades on a U.S. exchange.
What was the last price of CBAY stock?
CBAY closed at $32.48 on its final trading day, March 21, 2024, for a market value of about $3.73B.
What were Cymabay Therapeu's revenue and earnings in its last full fiscal year?
Cymabay Therapeu reported revenue of $31.07M and net income of -$105.4M in fiscal 2023, its last full year as a public company.
When did Cymabay Therapeu go public?
Cymabay Therapeu stock began trading on February 3, 2014.